Maria G. Pasmooij

Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case-Control Study.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 29, 2026

Factors influencing pharmaceutical companies' decisions to pursue compassionate use programs in the EU: a qualitative study in The Netherlands.

Journal: Journal of pharmaceutical policy and practice

Published: January 09, 2026

A new European platform for advancing regulatory science research.

Journal: Nature reviews. Drug discovery

Published: February 10, 2025

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.

Journal: European respiratory review : an official journal of the European Respiratory Society

Published: October 01, 2024

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.

Journal: Nature reviews. Drug discovery

Published: September 19, 2024

Dispensing Patterns of Inhaled Asthma Medication Before and During COVID-19 Among Young Adults in the Netherlands: A Retrospective Inception Cohort Study.

Journal: Clinical epidemiology

Published: September 18, 2024

The European Innovation Network as a hub for medicines innovation in Europe.

Journal: Nature reviews. Drug discovery

Published: March 12, 2024

International regulatory and publicly-funded initiatives to advance drug repurposing.

Journal: Frontiers in medicine

Published: February 17, 2024

Learning from European regulator-initiated studies for regulatory decision making.

Journal: Drug discovery today

Published: January 24, 2024

Report of the European Medicines Agency Conference on RNA-Based Medicines.

Journal: Nucleic acid therapeutics

Published: January 04, 2024

Drug repurposing for rare: progress and opportunities for the rare disease community.

Journal: Frontiers in medicine

Published: December 08, 2023

Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case-Control Study.

Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case-Control Study.

Factors influencing pharmaceutical companies' decisions to pursue compassionate use programs in the EU: a qualitative study in The Netherlands.

Factors influencing pharmaceutical companies' decisions to pursue compassionate use programs in the EU: a qualitative study in The Netherlands.

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations.

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations.

A new European platform for advancing regulatory science research.

A new European platform for advancing regulatory science research.

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024.

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.

Dispensing Patterns of Inhaled Asthma Medication Before and During COVID-19 Among Young Adults in the Netherlands: A Retrospective Inception Cohort Study.

Dispensing Patterns of Inhaled Asthma Medication Before and During COVID-19 Among Young Adults in the Netherlands: A Retrospective Inception Cohort Study.

The European Innovation Network as a hub for medicines innovation in Europe.

The European Innovation Network as a hub for medicines innovation in Europe.

International regulatory and publicly-funded initiatives to advance drug repurposing.

International regulatory and publicly-funded initiatives to advance drug repurposing.

Learning from European regulator-initiated studies for regulatory decision making.

Learning from European regulator-initiated studies for regulatory decision making.

Report of the European Medicines Agency Conference on RNA-Based Medicines.

Report of the European Medicines Agency Conference on RNA-Based Medicines.

Drug repurposing for rare: progress and opportunities for the rare disease community.

Drug repurposing for rare: progress and opportunities for the rare disease community.